相关实验视频

Updated: Jul 14, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

射频除与托利帕利马布联合治疗复发性肝细胞癌:一项前性受控试验

Zhenyu Wen¹, Junxiao Wang², Bo Tu³

¹Department of Public Health, Jilin University, Jilin, China.

Cancer medicine

|October 10, 2023

概括

将射频除 (RFA) 与托里帕利马布 (抗PD-1) 结合起来,可显著改善复发性肝细胞癌 (HCC) 患者的无复发存活率 (RFS). 这种组合治疗对于以前仅用RFA治疗的患者来说是安全有效的.

科学领域:

肝胆瘤学肝胆瘤学
免疫治疗是一种免疫疗法.
干预性放射学干预性放射学

背景情况:

复发性肝细胞癌 (HCC) 是一个重大的临床挑战.
射频除 (RFA) 是一种标准的治疗方法,但复发仍然很常见.
需要新的治疗策略来改善复发性HCC的治疗结果.

研究的目的:

评估将射频剥离 (RFA) 与托里帕利马布 (一种抗PD-1免疫疗法) 结合用于治疗复发性HCC的有效性和安全性.
为了比较组合治疗和单独的RFA之间的无复发生存 (RFS) 和安全概况.

主要方法:

这项研究涉及40名患有复发性HCC的患者,他们在2019年9月至2022年4月期间接受治疗.
患者接受了组合治疗 (RFA + toripalimab) 或单独使用RFA.
无复发生存率 (RFS) 是主要终点,安全是次要目标. 统计分析包括千平方测试,卡普兰-梅尔和考克斯的比例危险模型.

主要成果:

与单独使用RFA (8.2个月) 相比,组合疗法显示RFS的中位数显著更长 (15.4个月) (HR:0.44,p = 0.04).
18个月后的RFS率在组合组 (48.7%) 与RFA组 (18.8%) (p = 0.04) 相比显著更高.
两组治疗组之间没有观察到安全性的显著差异 (p > 0.05). 亚组分析显示,在60岁以下的患者,男性和Child-Pugh等级A的患者中,益处更大.

结论:

RFA和toripalimab (抗PD-1) 的组合是复发性HCC的有效和安全的治疗策略.
这种组合疗法显著改善了RFS在以前用RFA治疗的复发性HCC患者.
这些发现支持使用RFA加上抗PD-1免疫疗法作为选定的HCC患者的可行选择.

关键词:

这是一种抗PD-1药物.这是一个前性研究.无线电频率剥离方式复发性肝细胞癌复发性肝细胞癌在Toripalimab上使用.

更多相关视频

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis

Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis

Published on: March 3, 2023

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.